

# New regulations on in vitro diagnostic medical devices

Thursday, 3 November 2022

## Collection of links from the online event

You can find all the presentations [\[here\]](#)

You can find the general legal framework under point 2 and further information under the relevant headings. Note: This summary is for information purposes only and is not a complete summary of the relevant legal requirements.

---

### 1. Swissmedic as safety and industry monitoring authority for therapeutic products

Field safety corrective actions (FSCA): <https://fsca.swissmedic.ch/mep/>

---

### 2. New regulation

#### Laws, ordinances and international agreements

TPA: [Therapeutic Products Act SR 812.21](#)

HRA: [Human Research Act SR 810.30](#)

MedDO: [Medical Devices Ordinance SR812.213](#)

ClinO-MD: [Ordinance on Clinical Trials with Medical Devices SR 810.306](#)

IvDO: [Ordinance on In Vitro Diagnostic Medical Devices SR 812.219](#)

MDR: [Regulation \(EU\) on Medical Devices 2017/745](#)

IVDR: [Regulation \(EU\) on In vitro Diagnostic Medical Devices 2017/746](#)

MRA-2017 (not updated): [SR 0.946.526.81](#)

#### Additional information

Frequently Asked Questions: [FAQ](#)

Swissmedic Newsletter: [NEW > Registration form for Swissmedic News Services \(mailxpert.ch\)](#)

Roundtable on Medical Technology: [Round Table on Medical Technology \(RTMT\) \(swissmedic.ch\)](#)

Explanatory report: Ordinance on In Vitro Diagnostic Medical Devices and amendment of the Ordinance on Clinical Trials with Medical Devices:

[https://www.bag.admin.ch/dam/bag/de/dokumente/biomed/heilmittel/meprevision/BRB-mai2022/10\\_erlaeuterungen\\_ivdv\\_klinv-mep.pdf.download.pdf/10\\_erlaeuterungen\\_ivdv\\_klinv-mep\\_de.pdf](https://www.bag.admin.ch/dam/bag/de/dokumente/biomed/heilmittel/meprevision/BRB-mai2022/10_erlaeuterungen_ivdv_klinv-mep.pdf.download.pdf/10_erlaeuterungen_ivdv_klinv-mep_de.pdf)

Notice to stakeholders: [https://health.ec.europa.eu/latest-updates/notice-stakeholders-status-eu-switzerland-mutual-recognition-agreement-mra-vitro-diagnostic-medical-2022-05-24\\_en](https://health.ec.europa.eu/latest-updates/notice-stakeholders-status-eu-switzerland-mutual-recognition-agreement-mra-vitro-diagnostic-medical-2022-05-24_en)

EUDAMED3: [EUDAMED database - EUDAMED \(europa.eu\)](#)

---

### 3. Performance studies with IVDs

[KOFAM IVD categoriser](#)

[www.swissmedic.ch/performance-studies-en](http://www.swissmedic.ch/performance-studies-en)

Swissmedic information sheet: [www.swissmedic.ch/md-clinicaltrials-en](http://www.swissmedic.ch/md-clinicaltrials-en)

swissethics guidance document on 'Substantial modifications': [www.swissethics.ch](http://www.swissethics.ch)

---

### 4. Vigilance and market surveillance

Swissmedic Materiovigilance: [www.swissmedic.ch/md-materiovigilance](http://www.swissmedic.ch/md-materiovigilance)

Reporting incidents & FSCAs: [Reporting incidents & FSCAs \(vigilance\) \(swissmedic.ch\)](https://www.swissmedic.ch)

Economic operators: [Economic operators \(swissmedic.ch\)](https://www.swissmedic.ch)

Professionals and healthcare institutions / laboratories [Users \(swissmedic.ch\)](https://www.swissmedic.ch)

Procurement in health institutions: [Procurement \(swissmedic.ch\)](https://www.swissmedic.ch)

---

## 5. Manufacturer

### Sources, references and information

#### Manufacturer's obligations

Definition: [Art. 4 para. 1 let. e IvDO](https://www.swissmedic.ch)

Obligations: [Art. 39-43 IvDO](https://www.swissmedic.ch), Art. 10 IVDR

Assumption of manufacturer's obligations by third parties: Art. 16 paras. 1 and 2 IVDR

Notification to Swissmedic: [IVD notification \(swissmedic.ch\)](https://www.swissmedic.ch)

#### General Safety and Performance Requirements (GSPR)

[Art. 6 IvDO](https://www.swissmedic.ch), Annex I IVDR

Designated standards: [Art. 45 para. 4 TPA](https://www.swissmedic.ch), information from [Switec](https://www.switec.ch)

Common specifications: [Art. 45 para. 4 TPA](https://www.swissmedic.ch), see relevant [EU IVDR implementing regulations](https://www.swissmedic.ch), currently [Implementing Regulation \(EU\) 2022/1107](https://www.swissmedic.ch)

#### Performance evaluation

[Art. 39 para. 3 IvDO](https://www.swissmedic.ch), Art. 56 and Annex XIII IVDR

Clinical evidence: MDCG 2022-2

Software: MDCG 2020-1

#### Classification

[Art. 14 IvDO](https://www.swissmedic.ch), Annex VIII IVDR

Classification guidelines: MDCG 2020-16

Classification of software: MDCG 2019-11

#### Conformity assessment

[Art. 17 and 19 IvDO](https://www.swissmedic.ch), Art. 48 and Annexes IX-XI IVDR

Class D verification by NB: MDCG 2022-3

#### Legacy devices: Transitional periods and manufacturers' obligations

[Art. 81 -82 IvDO](https://www.swissmedic.ch)

Application of IVDR requirements to legacy devices: MDCG 2022-8

Significant changes: MDCG 2022-6

#### Post-market surveillance

System: [Art. 49 and 50 IvDO](https://www.swissmedic.ch), Art. 78 para. 3 IVDR

Post-market surveillance plan: [Art. 51 IvDO](https://www.swissmedic.ch), Annex III para. 1 IVDR

Post-market surveillance report (A&B): [Art. 52 IvDO](https://www.swissmedic.ch)

Safety report (C&D): [Art. 53-55 IvDO](https://www.swissmedic.ch)

General questions: [Frequently Asked Questions on medical devices \(swissmedic.ch\)](https://www.swissmedic.ch)

---

## 6. Authorised representatives, importers and distributors

### Further information on our website and especially in the information sheets

#### for economic operators:

<https://www.swissmedic.ch/swissmedic/en/home/medizinprodukte/marktzugang/pflichten-bevollmaechtigte.html>

**for healthcare institutions:** <https://www.swissmedic.ch/swissmedic/en/home/medical-devices/reprocessing---maintenance/beschaffung.html>

---